ALMR 8-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

ALMR ▼ -14.27% at T+20d

LONG call ✗ call lost -14.27% · α vs SPY -14.30% · entry $23.96 → $20.54

Next anchor: T+60d in 8w

Currently $20.13 · -15.98% from $23.96 entry

Entry anchored
May 8, 07:00 AM ET
via Databento tick

T+1d

-0.33%

call -0.33% · α -0.57%

$23.88

settled 4w ago

T+5d

-6.05%

call -6.05% · α -7.52%

$22.51

settled 26d ago

T+20d

-14.27%

call -14.27% · α -14.30%

$20.54

settled yesterday

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Alamar Biosciences reported Q1 2026 revenue of $26.0M, a 99% YoY increase, driven by 178% consumable revenue growth. Net loss widened to $21.3M from $7.7M due to a $8.6M convertible note remeasurement loss. The company completed a $197.8M net IPO in April 2026 and will provide full-year 2026 guidance in August.

Key Financial Metrics

Gross Margin

56%

Actionable Insight

Revenue growth of 99% YoY with accelerating consumable pull-through signals strong product-market fit for NULISA platform. The $197.8M IPO cash eliminates near-term funding risk. Watch for full-year guidance in August — if revenue trajectory sustains, the stock could re-rate higher. The $8.6M convertible note loss is non-cash and one-time.

Key Facts

Q1 2026 total revenue $26.0M, up 99% YoY from $13.1M
Consumable revenue grew 178% YoY to $14.0M
Gross margin expanded to 56% from 49% YoY
Net loss $21.3M vs $7.7M YoY, includes $8.6M convertible note remeasurement loss
Completed IPO in April 2026, raising $197.8M net proceeds
Full-year 2026 revenue guidance to be provided in August 2026

Financial Impact

Revenue nearly doubled YoY to $26.0M; gross margin improved 700 bps to 56%; IPO added $197.8M net cash to balance sheet

revenuegross margincash position

Risk Factors

Operating expenses grew 79% YoY, outpacing revenue growth rate
No full-year guidance provided yet — uncertainty on H2 trajectory
Net loss widened significantly due to convertible note remeasurement

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-213379
Document: ck0002104204-20260508.htm	0001193125-26-213379
Document: 0001193125-26-213379-index-headers.html	0001193125-26-213379
Document: 0001193125-26-213379-index.html	0001193125-26-213379
Document: 0001193125-26-213379.txt	0001193125-26-213379
8-K Data (Synthetic)	0001193125-26-213379

15 reports for ALMR

T+1T+5T+20T+60

86% Hit rate 6 of 7 directional calls best @ T+5▲ +21.32%Apr 17, 2026

Filters

Reports for ALMR — sortable, filterable
	Type				Now
May 8, 2026 4w ago	8-K BULLISH ★ 8/10	$23.96 $20.54	▼ −14.27%	▼ −14.30%	$20.13 (−15.98%)
May 8, 2026 4w ago	Press Release BULLISH ★ 7/10	$23.96 $20.54	▼ −14.27%	▼ −14.30%	$20.13 (−15.98%)
Apr 21, 2026 7w ago	EFFECT BULLISH ★ 7/10	$23.23 $20.86	▼ −10.20%	▼ −15.12%	$20.13 (−13.34%)
Apr 20, 2026 7w ago	8-K BULLISH ★ 8/10	$23.23 $20.86	▼ −10.20%	▼ −15.12%	$20.13 (−13.34%)
Apr 20, 2026 7w ago	Insider Cluster BULLISH ★ 7/10	$22.00 $20.86	▼ −5.18%	▼ −9.38%	$20.13 (−8.50%)
Apr 20, 2026 7w ago	Insider Cluster BULLISH ★ 7/10	$22.00 $20.86	▼ −5.18%	▼ −9.38%	$20.13 (−8.50%)
Apr 17, 2026 7w ago	424B4 BULLISH ★ 7/10	$22.00 $20.86	▼ −5.18%	▼ −9.38%	$20.13 (−8.50%)
Apr 17, 2026 7w ago	EFFECT BULLISH ★ 7/10	$22.00 $22.51	▲ +2.32%	▼ −3.05%	$20.13 (−8.50%)
Apr 17, 2026 7w ago	3 NEUTRAL ★ 2/10	$22.00 $22.51	▲ +2.32%	▼ −3.05%	$20.13 (−8.50%)
Apr 17, 2026 7w ago	3 NEUTRAL ★ 2/10	$22.00 $22.51	▲ +2.32%	▼ −3.05%	$20.13 (−8.50%)

US Market Status

Market Closed — Opens Thu (11h 11m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access